Analyst Expectations For Macrogenics's Future

In the latest quarter, 5 analysts provided ratings for Macrogenics MGNX, showcasing a mix of bullish and bearish perspectives.

Summarizing their recent assessments, the table below illustrates the evolving sentiments in the past 30 days and compares them to the preceding months.

The 12-month price targets assessed by analysts reveal further insights, featuring an average target of $18.0, a high estimate of $24.00, and a low estimate of $13.00. This current average has increased by 69.81% from the previous average price target of $10.60.

Deciphering Analyst Ratings: An In-Depth Analysis

In examining recent analyst actions, we gain insights into how financial experts perceive Macrogenics. The following summary outlines key analysts, their recent evaluations, and adjustments to ratings and price targets.

Key Insights:

• Action Taken: Analysts adapt their recommendations to changing market conditions and company performance. Whether they 'Maintain', 'Raise' or 'Lower' their stance, it reflects their response to recent developments related to Macrogenics. This information provides a snapshot of how analysts perceive the current state of the company.
• Rating: Providing a comprehensive analysis, analysts offer qualitative assessments, ranging from 'Outperform' to 'Underperform'. These ratings reflect expectations for the relative performance of Macrogenics compared to the broader market.
• Price Targets: Analysts set price targets as an estimate of a stock's future value. Comparing the current and prior price targets provides insight into how analysts' expectations have changed over time. This information can be valuable for investors seeking to understand consensus views on the stock's potential future performance.

Capture valuable insights into Macrogenics's market standing by understanding these analyst evaluations alongside pertinent financial indicators. Stay informed and make strategic decisions with our Ratings Table.

Stay up to date on Macrogenics analyst ratings.

If you are interested in following small-cap stock news and performance you can start by tracking it here.

Unveiling the Story Behind Macrogenics

Macrogenics Inc is a biotechnology company focused on discovering and developing antibody-based therapeutics for the treatment of cancer. Its product includes MARGENZA, which is for the treatment of adult patients with metastatic HER2-positive breast cancer. The company's strategy includes leveraging partnerships with a therapeutic focus geared toward developing a broad portfolio of pipeline candidates. The company also targets autoimmune disorders and infectious diseases. The company's intellectual property is characterized by its patent use to protect the composition of its product candidates and the technology used to create them.

A Deep Dive into Macrogenics's Financials

Market Capitalization Analysis: Reflecting a smaller scale, the company's market capitalization is positioned below industry averages. This could be attributed to factors such as growth expectations or operational capacity.

Revenue Challenges: Macrogenics's revenue growth over 3 months faced difficulties. As of 30 September, 2023, the company experienced a decline of approximately -75.09%. This indicates a decrease in top-line earnings. As compared to competitors, the company encountered difficulties, with a growth rate lower than the average among peers in the Health Care sector.

Net Margin: Macrogenics's net margin surpasses industry standards, highlighting the company's exceptional financial performance. With an impressive 168.84% net margin, the company effectively manages costs and achieves strong profitability.

Return on Equity (ROE): Macrogenics's ROE surpasses industry standards, highlighting the company's exceptional financial performance. With an impressive 9.6% ROE, the company effectively utilizes shareholder equity capital.

Return on Assets (ROA): Macrogenics's financial strength is reflected in its exceptional ROA, which exceeds industry averages. With a remarkable ROA of 5.44%, the company showcases efficient use of assets and strong financial health.

Debt Management: Macrogenics's debt-to-equity ratio is below the industry average at 0.18, reflecting a lower dependency on debt financing and a more conservative financial approach.

Understanding the Relevance of Analyst Ratings

Ratings come from analysts, or specialists within banking and financial systems that report for specific stocks or defined sectors (typically once per quarter for each stock). Analysts usually derive their information from company conference calls and meetings, financial statements, and conversations with important insiders to reach their decisions.

Analysts may enhance their evaluations by incorporating forecasts for metrics like growth estimates, earnings, and revenue, delivering additional guidance to investors. It is vital to acknowledge that, although experts in stocks and sectors, analysts are human and express their opinions when providing insights.

This article was generated by Benzinga's automated content engine and reviewed by an editor.